Publication | Closed Access

TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study

Phase 1/2Gastrointestinal OncologyMedicineColorectal CancerC-task ForceCancer TreatmentOncologyRadiation OncologyMolecular Oncology